Achieving success in the Developing Asian Pharmaceutical Sector 2007-2011

Will the economic growth in new Asian markets allow you to offset global problems? With the Japan market slow and stagnant what other countries in the region offer you the greatest opportunities and how can you succeed in them. This report tells you.

Asian Developing Markets for Pharmaceuticals, 2006-2011 delivers to you unique prospects for the largest developing pharmaceutical market - Asia.

This report predicts that all the leading developing markets will exhibit strong growth from 2006-2011. Rapid economic growth and large, under-served populations will drive that expansion in pharmaceutical revenues. There will be significant growth in sales of both branded and generic drugs through increasing demand from both public and private healthcare sectors.

This unique report concentrates on the following themes:

> Forecasts of sales revenues and growth rates for leading developing markets in Asia, from 2006-2011

> Drivers and opportunities in the markets you should be working in

> Restraints and threats in those markets

> Discussion of key players and important therapeutic areas

> Discussion of relevant regulatory, societal and economic issues

> Comparison of the prospects for revenuegeneration in Asia, Latin America and

> Central/Eastern Europe, with overall forecasts for those regions

> Who you should be working with and why

> Why you should buy this report:

To receive a comprehensive analysis of the prospects for developing regional and national markets for pharmaceuticals in Asia from 2006-2011, as well as comparative data for other developing regions

To discover predicted revenues, growth rates and other key metrics for Asian developing markets from 2006-2011

To determine the forces that influence pharmaceutical sales in the Asian developing markets:

Competitive characteristics of the market, both at - national and regional level

- Regulatory, technological, societal and political issues

- Drivers and restraints

- Strengths, weaknesses, opportunities and threats

The dominant pharmaceutical markets of North America, Western Europe and Japan currently account for approximately 85% of revenues for prescription drugs. However, there is concern about the relatively low growth of those established markets in recent years. Consequently, international pharmaceutical companies are very interested in raising their profile in the developing markets of Asia.

You cannot afford to ignore this expanding market. A small investment today will be the catalyst of a great return for your company tomorrow.

Unique benefits to you when you order this report

- Full searchable report when you buy the company or corporate editions

- Immediate access through our exclusive Reading Room

- You can access your report whichever country you are in without using harddrive space

- Primary research throughout. You will not find this information anywhere else

- Report stored in your reading room for ever

- Copies can be printed off for offline reading

- Packed with charts, analysis, figures, graphs and tables

Organizations listed:

Abbott Laboratories

Abdi Ibrahim

Ablomed

Actavis

Adamed

Akrikhin

Alkem

Alpharma

Apex International Clinical Research

Armstrong

AstraZeneca

Bagó

Barr Pharmaceuticals

Bayer

Berlin-Chemie

Bristol-Myers Squibb

Bryntsalov A

Cadila Healthcare

Choong Wae

Cipla

Dae Woong

Dexa Medica

Dong A

Dr Reddy’s Laboratories

Eczacibasi

Egis

Elea

Eli Lilly

F. Hoffman-La Roche

Fresenius

Gador

Gedeon Richter

Genovate Biotec

Geven

GlaxoSmithKline

Guangzhou Tainxin

Han Mi

Heilongjiang Haerbin Pharmaceutical

Hexal

Hoechst Marion Roussel

ICON

II Dong

Immunopreparat

Interbat

Ivax Pharmaceuticals

Jiangsu Lianyungang Hengrui

Johnson & Johnson

Kalbe Farma

Krka

KRKA D.D.

Lek

Menarini

Merck & Co

Merck KGaA

Merck Sharp Dohme

Moskhimpharmpreparaty

MSD Korea

Mylan Laboratories

Nicholas Piramal

Nizpharm

Novartis

Novo Nordisk

Nycomed

Omnicare CR

Otechestvennye Lekarstiva

Otsuka Pharmaceutical

Pascual Laboratories

Perlican

Pfizer

PHARM-CENTR

Pharmstandart

Phoenix

Pliva

Polfa Kutno

Polfa Warszawa

Polpharma SA

Protech Pharmaservice

Quintiles

Ranbaxy Laboratories

Roche

Roemmers

Sanbe Farma

Sandoz

Sanofi-Aventis

Schering Plough

Schwarz Pharmaceutical

Servier Pharmaceuticals

Siam Pharma

Soul-Pattinson

Sun Pharmaceutical Industries

Teva Pharmaceutical

Trans-India Acquisition Corporation

Unichem

United Laboratories

Veropharm

Virginia CRO

VIRION

Watson Pharmaceuticals

Wockhardt

Wyeth

Yangzijiang Pharmaceutical

Yuhan Company

Yung Shin Pharmaceutical Industries

Zentiva

Zydus Cadila

Lead Analyst: Dr Gordon Low Publication Date: 09/11/06 Pages: 139

Single user licence: The Report is delivered via an on-line reading room. One use access only, the report is in Flash format in a printable format.

Department: Report is delivered via an on line reading room. Five user access only, the report is in Flash format in a printable format.

Company/site wide licence: The report is delivered in email format as a PDF document with no locking system attached. The report can be loaded onto the company's intranet site.
Table of Contents

Price
Single User Licence $3998.00
Department Licence 5 Users $7998.00
Company-wide Intranet Licence $11,998.00